Products with Neuroprotection bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5236 | Pinusolide |
| 1. Pinusolide is a platelet activating factor ( PAF) antagonist, it may prove of therapeutic value in the treatment of hypotension . 2. Pinusolide has antileukemic potential, it not only decreases the proliferation activity of tumor cells at relatively low concentrations but specifically induces apoptosis at 100 microM via the mitochondrial pathway in the Burkitt lymphoma cell line BJAB. 3. Pinusolide attenuates blockade of insulin signaling by enhancing IRS-1 tyrosine phosphorylation by the activating the AMPK pathway, indicates the targeting of AMPK represents a new therapeutic strategy for hyperglycemia-induced insulin resistance and type 2 diabetes. 4. Pinusolide can protect neuronal cells from staurosporine (STS) -induced apoptosis, probably by preventing the increase in [Ca2+]i and cellular oxidation caused by STS, and indicate that it could be used to treat neurodegenerative diseases. 5. Pinusolide shows potent inhibition of 5-LO dependent LTC4 generation, which requires both suppression of calcium influx and JNK phosphorylation. | |
| BCN5256 | Gartanin |
| 1. Gartanin possesses potent antioxidant, anti-inflammatory, antifungal and antineoplastic properties. 2. Gartanin induces protective autophagy mainly by JNK-Bcl-2 pathway. 3. Gartanin is an androgen receptor degradation enhancer. 4. Gartanin is a potential neuroprotective agent against glutamate-induced oxidative injury partially through increasing Nrf-2-independed HO-1 and AMPK/SIRT1/PGC-1αsignaling pathways. 5. Gartanin has anti-proliferation effect in T98G cells, which is most likely via cell cycle arrest modulated by autophagy, which is regulated by PI3K/Akt/mTOR signalling pathway, while its anti-migration effect is most likely via suppression of MMP-2/-9 activity which is involved in MAPK signalling pathway. | |
| BCN5267 | Catalponol |
| 1. Catalponol can enhance dopamine biosynthesis by inducing TH activity and protect against L-DOPA-induced cytotoxicity in PC12 cells, which was mediated by the increased levels of cyclic AMP. | |
| BCN5304 | Cryptotanshinone |
| Cryptotanshinone is a potent STAT3 inhibitor with IC50 of 4.6 μM, and inhibits STAT3 Tyr705 phosphorylation in DU145 prostate cancer cells. It is also an AR inhibitor to suppress androgen/AR-mediated cell growth and PSA expression by blocking AR dimerization and the AR-coregulator complex formation. Cryptotanshinone has anti-atherosclerosis, neuroprotective, anti-cancer,and anti-neointimal formation activities. Cryptotanshinone reverses DEX-induced androgen excess and ovarian IR in mice through activation of insulin signaling and the regulation of glucose transporters and hormone-synthesizing enzymes, it has an inhibitory effect on MMP-9 production and migration of human aortic smooth muscle cells treated with TNF-alpha in a dose-dependent manner. | |
| BCN5319 | Jatrorrhizine |
| Jatrorrhizine has neuroprotective, antioxidative, anti-inflammatory, antihypercholesterolemic, and anti-hyperglycemia effects.Jatrorrhizine is expected to be developed as a new gastric prokinetic drug, it is metabolized by human CYP1A2 and multiple UGT1A isoforms. It has inhibitory activities against the expression of inducible NO syntase (iNOS) and cyclooxygenase-2 (COX-2), and can improve the utilization and excretion of cholesterol by up-regulating the mRNA and protein expression of LDLR and CYP7A1. | |
